Last update Feb. 5, 2022

Dextran

Very Low Risk

Safe. Compatible. Minimal risk for breastfeeding and infant.

High molecular weight glucose polymers. Used as plasma expanders in the treatment of hypovolemic shock and as artificial tears in dry eyes (xerophthalmia).

At the date of the last update, there was no published data available on its excretion in breast milk.

Its high molecular weight and high binding to plasma proteins make it unlikely to pass into human milk.

Its practically non-existent oral bioavailability makes it difficult for the infant to pass into plasma from ingested mothers’ milk.

The possibility of breastfeeding will depend on the clinical condition of the mother.

WHO List of Essential Medicines: compatible with breastfeeding. (WHO 2002)

Alternatives

We do not have alternatives for Dextran since it is relatively safe.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Dextran is also known as


Dextran in other languages or writings:

Tradenames

Main tradenames from several countries containing Dextran in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. ≈ 0 %
Molecular weight 15.000 - 160.000 daltons
Protein Binding alta - high %
VD 0.1 l/Kg
2 - 67 hours

References

  1. WHO / UNICEF. BREASTFEEDING AND MATERNAL MEDICATION Recommendations for Drugs in the Eleventh WHO Model List of Essential Drugs. Department of Child and Adolescent Health and Development (WHO/UNICEF) 2002 Full text (link to original source) Full text (in our servers)
  2. Terg R, Miguez CD, Castro L, Araldi H, Dominguez S, Rubio M. Pharmacokinetics of Dextran-70 in patients with cirrhosis and ascites undergoing therapeutic paracentesis. J Hepatol. 1996 Sep;25(3):329-33. Abstract
  3. Kienlen J, Mathieu-Daudé JC, Passeron D, Dellord A, d'Athis F, du Cailar J. [Pharmacokinetics and changes in the physical properties of blood and urine after administration of dextran 60000]. Ann Fr Anesth Reanim. 1990;9(6):495-500. Review. French. Abstract
  4. Klotz U, Kroemer H. Clinical pharmacokinetic considerations in the use of plasma expanders. Clin Pharmacokinet. 1987 Feb;12(2):123-35. Review. Abstract

Total visits

4,234

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by AELAMA of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM